Skip to main content
. 2021 Apr 16;100(15):e25180. doi: 10.1097/MD.0000000000025180

Figure 7.

Figure 7

Direct and indirect comparisons for ORR (A/C) and DCR (B/D) among Atez (atezolizumab), Durv (durvalumab), Pemb (pembrolizumab), Nivo (nivolumab), and Pla (placebo).